France Biotech presents twelfth annual Panorama of the Life Sciences survey results

18 December 2014

France Biotech, an association for life sciences entrepreneurs, has published the twelfth edition of its Panorama of the Life Sciences industry.

It has made several recommendations to implement a policy to promote the development of innovative life sciences companies. France Biotech recommends placing life science innovation at the heart of public health policies and strengthening and developing the number of venture capital investment funds by channeling 5% of French household life insurance towards investment in innovative companies.

It also advocates adapting the lifespan of FCICs (a form of mutual fund particular to France), and the status of jeune entreprise innovante, a program supporting innovative research and development investments, including with tax breaks. This is because the investment cycle in life sciences is longer than other sectors, which is a disadvantage being upheld by the current processes and protocols.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK